Candida albicans is the most prevalent opportunisti human fungal pathogen. The systemic candidiasis is associated with high morbidity and mortality rates. Understanding differences between C. albicans and mammalian molecular biology is critical to development of the next generation of antifungal therapeutics. This requires investigators to be able to quickly and precisely manipulate the genome of C. albicans.